Tsubota Laboratory Incorporated (4890.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−9.9x

Market Cap

JPY 7.74B

MomentumView details →

1D Return

+1.69%

YTD Return

−10.88%

RSI (14)

73.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−9.9x

Market Cap

JPY 7.74B

RSI (14)

73.4

MomentumView details →

1D Return

+1.69%

YTD Return

−10.88%

ProfitabilityView details →

Gross Margin

165.76%

Net Margin

−56.20%

EBITDA Margin

37.15%

ROE (TTM)

−36.11%

ROA (TTM)

−23.86%

Asset Turnover

0.40x

GrowthView details →

Revenue YoY

−45.00%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+19.27%

EPS CAGR 3Y

+48.21%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

3.17x

Quick Ratio

3.16x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

710.00M

Net Income (TTM)

−399.00M

Op. CF (TTM)

—

Next earningsNov 6, 2026 →

Latest newsMore news →

Tsubota Laboratory announced that the Phase 2a trial of TLM-001, an ophthalmic drug for meibomian gland dysfunction licensed to Maruho, achieved Last Patient Out on June 25, 2026.23d ago

Tsubota Laboratory announced that it achieved the final milestone under a license agreement with an overseas pharmaceutical company for non-clinical and partial clinical trial data, recognizing related revenue in Q1 FY2027.23d ago

Similar companies

Carna Biosciences,Inc.4572.T OncoTherapy Science,Inc.4564.T Kidswell Bio Corporation4584.T Nano Holdings,Inc.4571.T Solasia Pharma K.K.4597.T CellSource Co.,Ltd.4880.T Find similar companies →

Latest newsMore news →

Tsubota Laboratory announced that the Phase 2a trial of TLM-001, an ophthalmic drug for meibomian gland dysfunction licensed to Maruho, achieved Last Patient Out on June 25, 2026.23d ago Tsubota Laboratory announced that it achieved the final milestone under a license agreement with an overseas pharmaceutical company for non-clinical and partial clinical trial data, recognizing related revenue in Q1 FY2027.23d ago